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OBJECTIVES: Severe asthma is found in approximately 10% of patients with asthma. Some factors associated with worse asthma 
control include rhinitis, gastroesophageal reflux disease, vocal cord dysfunction (VCD), nasal polyposis and bronchiectasis. There-
fore, we evaluated the prevalence of these illnesses in patients with severe asthma.
METHODS: We conducted a retrospective analysis of data obtained from electronic medical records of patients with severe asthma 
between January 2006 and June 2008. Symptoms of rhinitis and gastroesophageal reflux disease were evaluated as well as intoler-
ance to nonsteroidal anti-inflammatory drugs. We evaluated the results of esophagogastroduodenoscopy, videolaryngoscopy and CT 
scans of the chest in order to confirm gastroesophageal reflux disease, nasal polyposis, vocal cord dysfunction and bronchiectasis. 
RESULTS: We evaluated 245 patients. Rhinitis symptoms were present in 224 patients (91.4%); 18 (7.3%) had intolerance to 
nonsteroidal anti-inflammatory drugs, and 8 (3.3%) had nasal polyposis. Symptoms of gastroesophageal reflux disease were 
reported for 173 (70.6%) patients, although the diagnosis of gastroesophageal reflux disease was confirmed based on esophago-
gastroduodenoscopy or laryngoscopy findings in just 58 (33.6%) patients. Vocal cord dysfunction was suspected in 16 (6.5%) and 
confirmed through laryngoscopy in 4 (1.6%). The patient records provided CT scans of the chest for 105 patients, and 26 (24.8%) 
showed bronchiectasis.
DISCUSSION: Rhinitis and gastroesophageal reflux disease were the most common comorbidities observed, in addition to 
bronchiectasis. Therefore, in patients with severe asthma, associated diseases should be investigated as the cause of respiratory 
symptoms and uncontrolled asthma.
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INTRODUCTION
The prevalence of asthma is increasing in most countries. 
The global prevalence ranges from 1 to 18%, which makes 
it a public health problem that has increasingly become 
of interest to researchers.1 Around 10% of asthma patients 
have severe asthma, and some of these cases are defined as 
difficult-to-control asthma. 
Difficult-to-control severe asthma, although accounting 
for no more than 5% of all asthma cases, is responsible for 
approximately 50% of the overall costs related to asthma 
treatment. It is also associated with greater morbidity and 
mortality. The risk of requiring treatment in the emergency 
room and of requiring hospitalization is 15 and 20 times 
greater, respectively, for such patients than for those with 
less severe forms of asthma.2-5
In individuals with severe asthma, comorbidities are 
common, with the most prevalent being gastroesophageal 
reflux disease (GERD), sinusitis, allergic rhinitis and nasal 
polyposis. All of these can lead to worsening of the asthma 
symptoms.6
Allergic rhinitis and allergic asthma are currently 
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recognized as manifestations of a single entity: chronic 
allergic respiratory disease, also known as “united airway 
disease”.7,8 The great majority of patients with asthma have 
rhinitis, which is itself a risk factor for the development of 
asthma.
Individuals with asthma often present with GERD, which 
has been shown to exacerbate asthma through mechanisms 
involving vagal nerve stimulation (esophagobronchial 
reflex) or microaspiration of gastric contents into the upper 
airways.9-11
Other diseases that are rare and sometimes difficult to 
diagnose, including vocal cord dysfunction (VCD) and 
allergic bronchopulmonary aspergillosis (ABPA), are also 
associated with worse asthma control.
The features of VCD include episodes of involuntary 
paradoxical movements caused by vocal cord adduction 
during inspiration, resulting in airway obstruction. Although 
VCD can be seen in patients with asthma, it can also occur 
in an isolated form in individuals without respiratory 
disease.12,13
Aspirin-induced asthma (AIA) is a clinical entity 
characterized by asthma and intolerance to aspirin or 
nonsteroidal anti-inflammatory drugs (NSAIDs).14 AIA and 
nasal polyposis are associated with an increase in asthma 
severity.14,15
Asthma and bronchiectasis coexist in many patients, 
and it has been shown that bronchiectasis can contribute 
to severe and difficult-to-control asthma with pulmonary 
complications.16
In order to improve the treatment of patients with severe 
asthma and to control the disease, comorbidities must be 
taken into consideration, and it is important to treat these 
conditions simultaneously.
We investigated the occurrence of rhinitis, intolerance to 
NSAIDs, nasal polyposis, GERD, VCD and bronchiectasis 
in patients with severe asthma.
MATERIALS AND METHODS
We conducted a retrospective analysis of data obtained 
from electronic medical records between January 2006 and 
June 2008 for patients who met the 2008 Global Initiative 
for Asthma (GINA) criteria for diagnosis of severe persistent 
asthma.1
The patients were asked about symptoms of rhinitis, 
GERD and intolerance to NSAIDs. Rhinorrhea, nasal 
pruritus, sneezing and congestion were all considered to 
be symptoms consistent with rhinitis. The severity and 
frequency of the symptoms were defined according to the 
criteria established in the World Health Organization review 
entitled Allergic Rhinitis and Its Impact on Asthma (ARIA).7
Regurgitation, heartburn and retrosternal discomfort were 
considered to be suggestive of GERD. Only patients 
presenting specific complaints of exacerbation resulting 
from the use of aspirin or NSAIDs were considered to be 
intolerant to those medications.
A diagnosis of VCD was suspected in patients who 
reported worsening of symptoms or attacks in situations 
of emotional stress, were refractory to routine asthma 
treatment, presented cervical inspiratory wheezing, and had 
a peripheral oxygen saturation that remained above 95% 
even during severe attacks. Suspicion of VCD was also 
raised for patients in whom spirometry revealed flattening 
of the inspiratory loop of the flow-volume curve, which 
is suggestive of extrathoracic obstruction, and in those 
presenting a difficult-to-control clinical profile with normal 
or only slightly altered pulmonary function. Thus, VCD was 
considered when there was a discrepancy between clinical 
features, laboratory exams and treatment. 
The study also included esophagogastroduodenoscopy 
(EGD), videolaryngoscopy and high-resolution computed 
tomography (CT) scans of the chest. Findings that could 
be consistent with GERD varied from mild to severe 
esophagitis, as seen under direct EGD visualization. Other 
clinical findings suggestive of GERD were seen under 
videolaryngoscopy as mild to severe posterior laryngitis. 
The results of endoscopic examination of the larynx were 
considered consistent with VCD when there was two-
thirds closure of the vocal cords with a diamond-shaped 
opening occurring posteriorly during inspiration. The same 
examination was used to confirm the presence of nasal 
polyps. We also evaluated CT scans of the chest in order to 
identify bronchiectasis.
RESULTS
We evaluated 245 patients, 194 females and 51 males, 
all of whom were being treated with inhaled corticosteroids. 
Six patients (2.5%) were also receiving oral corticosteroids 
in an attempt to control their asthma. The mean patient age 
was 57.8 years, with a range of 21-85 years. Lung function 
tests and levels of asthma control are summarized in table 1.
Rhinitis was seen in 224 patients (91.4%), and the 
majority of these patients had persistent and moderate-to-
severe rhinitis (Figures 1 and 2). 
Intolerance to NSAIDs or nasal polyposis was found in 
21 patients (8.5%). There were 13 patients with intolerance 
to NSAIDs who did not have nasal polyps, and there were 3 
patients with nasal polyposis who did not report intolerance 
to NSAIDs (Figure 3). 
Symptoms of GERD were reported for 173 (70.6%) of 
the patients evaluated, although the diagnosis of GERD was 
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confirmed based on the previously cited criteria in just 58 
(33.6%) (Figure 4).
Among the 245 asthma patients evaluated, VCD 
was suspected in 16 (6.5%) and confirmed through 
videolaryngoscopy in 4 (1.6%).
CT scans of the chest were taken for 105 patients, of 
whom 26 (24.8%) showed bronchiectasis.
DISCUSSION
Although only 10% of asthma cases are classified as 
severe, such cases are responsible for greater morbidity and 
mortality. In addition, other factors and comorbidities such 
as GERD, rhinosinusitis and VCD contribute to poor asthma 
control, although the exact impact these factors have on the 
severity of the disease has not been well established.6
The prevalence of rhinitis among patients with asthma is 
Table 1 - Demographic data, baseline characteristics, corti-
costeroid treatment and lung function (all patients)
n (female/male) 245 (194/51)
Age (years), median (range) 57.8 (21 – 85)
Corticosteroid treatment
   Under ICS treatment, n (%) 245 (100%)
   Under OCS treatment, n (%) 6 (2.5%)
Lung function - Degree of severity# (%)
   Normal 1.3
   Mild 23.2
   Moderate 23.2
   Moderately severe 24.3
   Severe 25.0
   Very severe 3.0
FEV1 % predicted, median (range) 60 (32 – 99)
Levels of asthma control* (%)
   Controlled 5.4
   Partly controlled 62.3
   Uncontrolled 32.3
ICS, inhaled corticosteroid; OCS, oral corticosteroid; FEV1, forced 
expiratory volume in 1s
# ATS/ERS Task Force: Standardisation of Lung Function Testing.17
* GINA Executive Summary.1
Figure 1 - Frequency of rhinitis symptoms among severe asthma patients 
(defined according to the criteria established in Allergic Rhinitis and its 
Impact on Asthma – ARIA7)
Figure 2 - Severity of rhinitis symptoms among severe asthma patients 
(defined according to the criteria established in Allergic Rhinitis and its 
Impact on Asthma – ARIA7).
Figure 3 – Frequency of intolerance to nonsteroidal anti-inflammatory 
drugs (NSAIDs) and nasal polyposis.  White color represents intolerance 
to NSAIDs;  Black color represents nasal polyposis
Figure 4 – Patients with gastroesophageal reflux disease (GERD) symptoms 
and investigation with esophagogastroduodenoscopy (EGD) and videolar-
yngoscopy. Confirmation of GERD was based on findings of esophagitis 
or laryngitis
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around 75 to 80%.7 Various studies have demonstrated that 
among atopic diseases, asthma and rhinitis are the ones most 
often seen in combination. In addition, allergic rhinitis is 
considered a major risk factor for the development of asthma, 
as has been well documented in various countries, including 
Brazil, in the International Study of Asthma and Allergy in 
Childhood.18,19 The prevalence of rhinitis in the patients with 
severe asthma evaluated in the present study, however, was 
higher than that reported in the majority of studies found 
in the literature. We believe that the high prevalence in our 
study can be attributed to the fact that our patient population 
had severe asthma.7 Some studies have demonstrated that 
the presence of severe rhinitis in a patient with asthma is 
associated with a less favorable outcome. It is also possible 
that the presence of more than one allergic respiratory disease 
will lead to an allergy specialist referral. In addition, it has 
been shown that the treatment of nasal symptoms can be 
beneficial to the lower respiratory tract, reducing the number 
of emergency room visits and hospitalizations and limiting 
bronchial hyperresponsiveness.19,20
Although hypersensitivity to NSAIDs and aspirin affects 
only 0.6-2.5% of the general population of adults, it occurs 
in 5-20% of adults with asthma.21 In our sample, only 
3.2% of the patients reported asthma exacerbation after the 
use of NSAIDs; however, this finding might indicate that 
many patients are not able to perceive such exacerbation, 
as has previously been demonstrated. In a study conducted 
in Europe involving 500 patients diagnosed with aspirin-
intolerant asthma, 90 (18%) were unable to perceive 
worsening symptoms prior to the provocation test.21 In the 
present study, only the clinical profile of NSAID-induced 
bronchospasm was considered. None of the patients 
underwent a challenge test.
Asthma and GERD frequently coexist.22 Concomitance 
between symptoms of dyspnea and reflux is quite common, 
and large-scale studies have shown that the degree of 
reflux can be as much as 60% greater in those with asthma 
as compared to individuals without asthma.23 In a study 
conducted in the United Kingdom, the prevalence of 
GERD symptoms among patients with difficult-to-control 
asthma was found to be 75%, which is comparable to the 
findings in our sample.24 In the same study, however, 24-h 
pH-metry revealed the true prevalence to be only 55%. In 
the present study, the patients were submitted to EGD and 
videolaryngoscopy, through which 58 patients (23.6%) were 
diagnosed with concomitant asthma and GERD. Not all of 
our patients, however, underwent these tests. 
Despite the fact that VCD has been increasingly 
studied, its prevalence has yet to be well defined. In Brazil, 
the reported prevalence of VCD is around 17.5% among 
patients with severe asthma.12 In our study, the patient charts 
indicated that VCD was suspected in only 6.5% of cases. 
We believe that VCD is under-diagnosed, however, since 
the diagnosis was confirmed in more than 16 patients at our 
outpatient clinic.25,26
It is common to see abnormal CT scan results in those 
with asthma, as previously reported by several authors. In 
addition to abnormalities such as hyperinflation, mucoid 
impaction, acinar pattern, lobar collapse and bronchial wall 
thickening, which are expected in patients with asthma, other 
less common findings such as bronchiectasis are increasing 
in frequency. The reported incidence of bronchiectasis 
among asthma patients is between 37% and 65%. The use of 
CT for the diagnosis of bronchiectasis has been validated in 
various studies in which the patients were submitted to CT 
and bronchogram.27
Autopsy studies have shown that 15-20% of patients 
who died from exacerbation of asthma had bronchiectasis, 
most often in the upper lobes. One hypothesis to explain 
the prevalence of bronchial dilation in asthma patients is 
destruction of the bronchi by an inflammatory process or 
recurrent infection. In our study, 24.8% of 105 patients who 
underwent CT showed bronchiectasis. Some of these patients 
could have also had ABPA, which is difficult to diagnose. It 
has been reported that the majority of patients do not meet 
all of the diagnostic criteria simultaneously, and many such 
patients are receiving corticosteroid therapy, which can mask 
the symptoms.27
CONCLUSIONS
Rhini t is  and GERD were the most  common 
comorbidities observed, in addition to bronchiectasis. 
Therefore, in patients with severe asthma, associated 
diseases should be investigated as the cause of respiratory 
symptoms and uncontrolled asthma.
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